Suppr超能文献

Erdheim-Chester病:从眼科角度看两例病例

Erdheim-Chester Disease: Two cases from an ophthalmic perspective.

作者信息

Brodie James, Zhou Sean, Makkuni Damodar, Beadsmoore Clare, Mukhtyar Chetan, Saada Janak, Bowles Kristian M, Beigi Bijan, Burton Ben J L

机构信息

Department of Ophthalmology, James Paget University Hospitals NHS Trust, Great Yarmouth, Norfolk, United Kingdom.

Department of Ophthalmology, Norfolk and Norwich University Hospital NHS Trust, Norwich, Norfolk, United Kingdom.

出版信息

Am J Ophthalmol Case Rep. 2020 Nov 2;20:100984. doi: 10.1016/j.ajoc.2020.100984. eCollection 2020 Dec.

Abstract

PURPOSE

We report two patients who presented initially to ophthalmology clinics with symptoms and signs of orbital inflammation that led to a diagnosis of Erdheim-Chester Disease (ECD).

OBSERVATIONS

ECD is a rare form of non-Langerhans cell histiocytosis (LCH) which is characterised by multi-system organ involvement and poor prognosis with standard therapies. Both patients were positive for the V600E mutation on genetic testing and were treated with the inhibitors Vemurafenib and Dabrafenib respectively. These cases highlight the variable clinical presentation and course of ECD, the classical radiological and histopathological findings, and the high degree of clinical suspicion necessary to reach this diagnosis.

CONCLUSIONS AND IMPORTANCE

The combination of xanthelasma and bilateral, diffuse intraconal orbital masses must suggest to the clinician the possibility of ECD; and consideration to arrange further investigation with a full body CT or FDG PET/CT scan should be given, even in the absence of wider systemic symptoms or signs. With the advent of targeted therapies such as inhibitors, it is of even more importance that a diagnosis of ECD is established in a timely manner in order to give these patients the best chance of reduced morbidity and increased survival.

摘要

目的

我们报告两名最初因眼眶炎症的症状和体征就诊于眼科诊所,最终被诊断为厄尔德海姆-切斯特病(ECD)的患者。

观察结果

ECD是一种罕见的非朗格汉斯细胞组织细胞增多症(LCH),其特征为多系统器官受累,且采用标准疗法时预后较差。两名患者基因检测均显示V600E突变阳性,分别接受了维莫非尼和达拉非尼抑制剂治疗。这些病例突出了ECD临床表现和病程的多样性、典型的影像学和组织病理学表现,以及做出该诊断所需的高度临床怀疑。

结论与重要性

睑黄瘤与双侧弥漫性眶内肿块并存应提示临床医生考虑ECD的可能性;即使没有更广泛的全身症状或体征,也应考虑安排全身CT或FDG PET/CT扫描进行进一步检查。随着维莫非尼和达拉非尼抑制剂等靶向治疗的出现,及时确诊ECD变得更加重要,以便为这些患者提供降低发病率和提高生存率的最佳机会。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/31b7/7649437/1dc4e65f14ba/gr1.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验